Pharmacologic treatment of irritable bowel syndrome. Position statement of the Asociación Mexicana de Gastroenterología, 2024 J.M. Remes-Troche; E. Coss-Adame; M. Schmulson; K.R. García-Zermeño; M. Amieva-Balmori; R. Carmona-Sánchez; O. Gómez-Escudero; P.C. Gómez-Castaños; M.E. Icaza-Chávez; A. López-Colombo; E.C. Morel-Cerda; M.Á. Valdovinos-Díaz; L.R. Valdovinos-García; A.S. Villar-Chávez;

Prevalence of metabolic associated fatty liver disease (MAFLD) in patients with gallstone disease. Study on a cohort of cases in South-Southeastern Mexico F. Roesch-Dietlen; A.G. Pérez-Morales; P. Grube-Pagola; M. González-Santes; F. Díaz-Roesch; A. Triana-Romero; L. Roesch-Ramos; J.M. Remes-Troche; M. Cruz-Aguilar;

Latin American consensus on the quality indicators for comprehensive care clinics for patients with inflammatory bowel disease: PANCCO-GETECCU J.K. Yamamoto-Furusho; D. Andrade; J. Barahona; S. Bautista; F. Bosques-Padilla; J. de Paula; M.T. Galiano; B. Iade; F. Juliao-Baños; G. Otoya; F. Steinwurz; E. Torres; G. Veitia; M. Barreiro-de Acosta;